BioCentury
ARTICLE | Politics, Policy & Law

Trans-Pacific politics

Pharma and biotech companies weighing political responses to TPP deal

October 12, 2015 7:00 AM UTC

The biopharma industry is again at the center of a massive political dispute, this time over the Trans-Pacific Partnership. After fighting and losing a battle to persuade or force the rest of the world to adopt 12 years of biologics exclusivity, biotech and pharma CEOs are focused on shoring up support in the U.S., where presidential candidates are pummeling them as profiteers.

U.S. Trade Representative Michael Froman announced last week that TPP sets a five-year minimum period of exclusivity augmented by regulatory and administrative requirements that could further delay biosimilars launches for an unspecified period. ...